Diabetes complications and comorbidities: Cardiovascular disease

Journal articles and book chapters

08-23-2018 | Empagliflozin | Article

Real‐world opportunity of empagliflozin to improve blood pressure control in African Americans with type 2 diabetes: An NCDR® “research‐to‐practice” project from the Diabetes Collaborative Registry (DCR)

Arnold SV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13510

08-22-2018 | Hypertension | Article

A comparison of the 2017 American College of Cardiology/American Heart Association blood pressure guideline and the 2017 American Diabetes Association diabetes and hypertension position statement for US adults with diabetes

Munter P et al. Diabetes Care 2018: dc181307. doi: 10.2337/dc18-1307

08-18-2018 | Bone health | Review | Article

Lifestyle management of diabetes: implications for the bone-vascular axis

Pieralice S et al. Curr Diab Rep 2018; 18: 84. doi: 10.1007/s11892-018-1060-y

08-17-2018 | Cardiovascular outcomes | Article

Trends and disparities in cardiovascular mortality among US adults with and without self-reported diabetes mellitus, 1988–2015

Cheng YJ et al. Diabetes Care 2018: dc180831. doi: 10.2337/dc18-0831

08-17-2018 | Cardiovascular disorders | Article

Age-related differences in glycemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: A cross-sectional study from the Australian National Diabetes Audit

Nanayakkara N et al. BMJ Open 2018; 8: e020677. doi: 10.1136/bmjopen-2017-020677

08-06-2018 | Cardiovascular outcomes | Article

Glycemic variation and cardiovascular risk in the Veteran’s Affairs Diabetes Trial

Zhou JJ et al. Diabetes Care 2018: dc180548. doi: 10.2337/dc18-0548

08-02-2018 | Cardiovascular disorders | Article

Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes

Yun JS et al. Cardiovasc Diabetol 2018; 17: 109. doi: 10.1186/s12933-018-0752-6

08-02-2018 | Diabetic foot | Article

The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial

Dhatariya K et al. Diabetes Care 2018: dc181094. doi: 10.2337/dc18-1094

07-23-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

07-17-2018 | Heart failure | Article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

07-14-2018 | Metformin | Review | Article

Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach

Harrington JL et al. Curr Diab Rep 2018; 18: 64. doi: 10.1007/s11892-018-1035-z

07-04-2018 | Mental health | Article

Factors associated with type 2 diabetes in patients with vascular dementia: A population-based cross-sectional study

Liu CL et al. BMC Endocr Disord 2018; 18: 45. doi: 10.1186/s12902-018-0273-z

07-03-2018 | Type 2 diabetes | Article

Adiposity-mortality relationships in type 2 diabetes, coronary heart disease, and cancer subgroups in the UK Biobank, and their modification by smoking

Jenkins DA et al. Diabetes Care 2018. doi: 10.2337/dc17-2508

07-02-2018 | Cardiovascular disorders | Article

The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study

Peters KE et al. Diabetes Res Clinc Prac 2018; 143: 62–70. doi: 10.1016/j.diabres.2018.06.005

06-30-2018 | Metformin | Review | Article

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

06-27-2018 | Metformin | Article

Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan

Matsuura N et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0361-3

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

06-23-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

06-23-2018 | Heart failure | Article

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: A real-world nationwide population-based cohort study

Kim YG et al. Cardiovasc Diabetol 2018; 17: 91. doi: 10.1186/s12933-018-0737-5

06-23-2018 | Gestational diabetes | Article

Maternal gestational diabetes mellitus and the risk of subsequent pediatric cardiovascular diseases of the offspring: A population-based cohort study with up to 18 years of follow up

Leybovitz-Haleluya N et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1176-1

Next Previous